Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details)

v3.21.1
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Apr. 01, 2021
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue [Line Items]      
Total revenue   $ 473 $ 2,754
Period before expiration to be considered as inventory   6 months  
Allowance for returns   $ 2,900  
Millipred | Teva | Subsequent Event      
Disaggregation of Revenue [Line Items]      
Percent of net profit for installment payments 50.00%    
Installment payment $ 500    
Product Revenue      
Disaggregation of Revenue [Line Items]      
Total revenue   $ 473 $ 2,754
Sales Revenue | Customer Concentration Risk | Major Customer Number One      
Disaggregation of Revenue [Line Items]      
Concentration risk percentage   67.00%  
Sales Revenue | Customer Concentration Risk | Major Customer Number Two      
Disaggregation of Revenue [Line Items]      
Concentration risk percentage   18.00%  
Sales Revenue | Customer Concentration Risk | Major Customer Number Three      
Disaggregation of Revenue [Line Items]      
Concentration risk percentage   15.00%